A bandage made of heart tissue developed by U of T scientists

Researchers at the University of Toronto have created an injectable bandage made out of lab-grown heart tissue. About the size of a postage stamp, the heart patch could be used to repair tissues damaged in heart attacks without the need for invasive surgery.

Science has come a long way in helping damaged organs to get back on the path to recovery and repair, including for the heart, which can suffer tissue damage as a result of a myocardial infraction. And preventing the development of scar tissue on the heart muscle is a major focus, as scarring can impede the heart’s ability to pump blood.

To that end, cardiac patches have been devised that can be either stuck or stitched onto the heart, which can encourage the growth of healthy cells, blood vessels and tissues and allow for better transmission of electrical impulses across any scar tissue that does develop.

A bandage made of heart tissue has its complications…

The problem? Open-heart surgery to stick on the patch or scaffolding is not always an option, especially for heart attack patients whose heart functioning has just been compromised. “If an implant requires open-heart surgery, it’s not going to be widely available to patients,” says professor Milica Radisic, of the U of T’s Institute of Biomaterials and Biomedical Engineering and study co-author, in a press release. ”It’s just too dangerous.”

To get around the problem, researchers devised an injectable heart patch, made of a degradable polymer scaffold seeded with lab-grown heart cells. Just one square centimetre in size, the AngioChip is foldable yet has shape memory so that once it emerges from the needle, it unfolds, as seen in this video, so that it can cover the intended tissue.

So far, the researchers have been able to test their creation on both rats and pigs and have met with success, finding that compared with patches put in place by open heart surgery, the AngioChip produced equivalent results in terms of vascularization, microphage recruitment and cell survival.

“When we saw that the lab-grown cardiac tissue was functional and not affected by the injection process, that was very exciting,” says Miles Montgomery, PhD candidate in Professor Radisic’s lab, who has been working on the AngioChip for three years. “Heart cells are extremely sensitive, so if we can do it with them, we can likely do it with other tissues as well.”

The next step will be to assess the long-term stability of the patches and determine how well they aid in cardiac functioning. The team is also looking into using their injectable patch on other organs, like the liver. “You could customize this platform, adding growth factors or other drugs that would encourage tissue regeneration,” says Radisic. “I think this is one of the coolest things we’ve done.”

The Heart and Stroke Foundation reports that heart failure —the inability of the heart to pump blood effectively, most commonly caused by heart attack— is on the rise in Canada, with 600,000 Canadian currently living with the condition and 50,000 more being diagnosed every
year.

Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

This company’s deal with Anthropic is huge, analyst says

Riot Platforms’ (Riot Platforms Stock Quote, Chart, News, Analysts, Financials NASDAQ:RIOT) new 910-megawatt data centre lease at its Corsicana campus… [Read More]

20 hours ago

AIRO Group Holdings is a buy, this analyst says

Roth Capital Partners analyst Craig Irwin initiated coverage of AIRO Group Holdings (Airo Group Holdings Stock Quote, Chart, News, Analysts,… [Read More]

20 hours ago

Decisive Dividend Corporation is a buy, this analyst says

Beacon Securities analyst Russell Stanley maintained his “Buy” rating and $12.50 target on Decisive Dividend Corporation (Decisive Dividend Corporation Stock… [Read More]

21 hours ago

5N Plus: this analyst just hiked his price target

Ventum Capital Markets analyst Daniel Lavoie raised his target on 5N Plus (5N Plus Stock Quote, Chart, News, Analysts, Financials… [Read More]

2 days ago

What to make of the Organigram, Aurora Cannabis deal?

Organigram Global (Organigram Global Stock Quote, Chart, News, Analysts, Financials TSX:OGI) has agreed to acquire Aurora Cannabis for approximately $561-million… [Read More]

2 days ago

Is Thinkific (TSX:THNC) a buy right now?

Thinkific Labs’ (Thinkific Labs Stock Quote, Chart, News, Analysts, Financials TSX:THNC) third-quarter results suggest recent price increases and growth in… [Read More]

2 days ago